FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315703251> ?p ?o ?g. }

• W4315703251 endingPage "e61" @default.
• W4315703251 startingPage "e61" @default.
• W4315703251 abstract "Hypertension Research will launch the special issue “A recent advance in renal denervation to clinical practice” in 2023 (Figure). Since the first proof-of-concept study in 2009, it has been passed for 13 years, the renal denervation is going to be introduced into clinical practice. The new clinical trials using the sham-control group have been performed. The meta-analysis and systematic review demonstrated that renal denervation is effective to reduce 24-hr blood pressure (BP), regardless of denervation techniques (Hypertens Res 2022;45:210–220). In 2022, the 2 major sham-controlled pivotal trials using the 2 different denervation techniques will be released. These study subjects had uncontrolled hypertension even medicated with one or more drugs. One is the SPYRAL On-Med Pivotal trial using the radiofrequency denervation technique and another is RADIANCE II trial using ultrasound technique, in which the trial, the Otsuka Holdings Co. Ltd (ReCor Medical Inc.). Inc released information on positive results in the market news. In addition, a recently longer follow-up result of SPYRAL On-Med feasibility study demonstrated a long-term BP lowering effect for 24 hours persisted for at least 3 years (Lancet 2022;399:1401–1410). Especially, even after initiating the medication titration, in those with drug-resistant hypertension, who were medicated up to 3 or more drugs, a significant difference in the nighttime and morning BPs between the renal denervation group and sham-controlled groups was overt (ISH2022, Rapid online publication in Hypertens Res). This indicates that renal denervation exhibit an “always on” BP lowering effect throughout 24 hours, which covers nighttime and morning periods, the “pits’ fall” time of medication. Recently guidelines/guidance and consensus statement include RDN in the option of antihypertensive treatment strategy. Positioning of renal denervation in the total management of hypertension in combination with non-pharmacological intervention and medication should be discussed. In addition, the patient preference studies demonstrated a consistently significant number of hypertensive patients preferred renal denervation. Cost-effectiveness should be soon addressed before clinical use. Once 2 pivotal trials demonstrated clearly clinically meaningful positive results, renal denervation will be accepted to introduce into clinical practice. During the clinical practice after regulatory approval, the residual challenges of renal denervation such as how to detect the responders and how to assess the successful endpoints of the procedures should be addressed in real-world studies. The Asia Renal Denervation Consortium consensus conference of Asian physicians actively performing renal denervation has been recently convened to share up-to-date information and regional perspectives, with the goal of consensus on RDN in Asia (Hypertension 2020;75:590–602)." @default.
• W4315703251 created "2023-01-12" @default.
• W4315703251 creator A5049406946 @default.
• W4315703251 date "2023-01-01" @default.
• W4315703251 modified "2023-10-02" @default.
• W4315703251 title "S-26-5: RENAL DENERVATION IN ASIA: GUIDELINES AND PERSPECTIVES IN CLINICAL PRACTICE" @default.
• W4315703251 doi "https://doi.org/10.1097/01.hjh.0000913316.89041.31" @default.
• W4315703251 hasPublicationYear "2023" @default.
• W4315703251 type Work @default.
• W4315703251 citedByCount "0" @default.
• W4315703251 crossrefType "journal-article" @default.
• W4315703251 hasAuthorship W4315703251A5049406946 @default.
• W4315703251 hasBestOaLocation W43157032511 @default.
• W4315703251 hasConcept C126322002 @default.
• W4315703251 hasConcept C164705383 @default.
• W4315703251 hasConcept C1862650 @default.
• W4315703251 hasConcept C2776805190 @default.
• W4315703251 hasConcept C2779974597 @default.
• W4315703251 hasConcept C2780177628 @default.
• W4315703251 hasConcept C3019558611 @default.
• W4315703251 hasConcept C535046627 @default.
• W4315703251 hasConcept C71924100 @default.
• W4315703251 hasConcept C84393581 @default.
• W4315703251 hasConceptScore W4315703251C126322002 @default.
• W4315703251 hasConceptScore W4315703251C164705383 @default.
• W4315703251 hasConceptScore W4315703251C1862650 @default.
• W4315703251 hasConceptScore W4315703251C2776805190 @default.
• W4315703251 hasConceptScore W4315703251C2779974597 @default.
• W4315703251 hasConceptScore W4315703251C2780177628 @default.
• W4315703251 hasConceptScore W4315703251C3019558611 @default.
• W4315703251 hasConceptScore W4315703251C535046627 @default.
• W4315703251 hasConceptScore W4315703251C71924100 @default.
• W4315703251 hasConceptScore W4315703251C84393581 @default.
• W4315703251 hasIssue "Suppl 1" @default.
• W4315703251 hasLocation W43157032511 @default.
• W4315703251 hasLocation W43157032512 @default.
• W4315703251 hasOpenAccess W4315703251 @default.
• W4315703251 hasPrimaryLocation W43157032511 @default.
• W4315703251 hasRelatedWork W115922469 @default.
• W4315703251 hasRelatedWork W1975584653 @default.
• W4315703251 hasRelatedWork W2033541488 @default.
• W4315703251 hasRelatedWork W2050943580 @default.
• W4315703251 hasRelatedWork W2094014018 @default.
• W4315703251 hasRelatedWork W2207553984 @default.
• W4315703251 hasRelatedWork W2387230403 @default.
• W4315703251 hasRelatedWork W2806821231 @default.
• W4315703251 hasRelatedWork W2976854704 @default.
• W4315703251 hasRelatedWork W2997898657 @default.
• W4315703251 hasVolume "41" @default.
• W4315703251 isParatext "false" @default.
• W4315703251 isRetracted "false" @default.
• W4315703251 workType "article" @default.